CompletedPhase 2NCT00523159
IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease
Studying Clear cell renal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Immatics Biotechnologies GmbH
- Principal Investigator
- Alexandra Kirner, PhD, MDImmatics Biotechnologies GmbH
- Intervention
- Endoxana, IMA901, Leukine(drug)
- Enrollment
- 68 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2007 – 2009
Study locations (30)
- Medizinische Universität Salzburg - Universitätsklinik für Innere Medizin III, Salzburg, Austria
- National Oncology Hospital - Urology, Sofia, Bulgaria
- Regional Oncodispensary with inpatient sector-Sofia District, Sofia, Bulgaria
- Charité Campus Mitte-Klinik für Urologie, Berlin, Germany
- Charité Campus Benjamin Franklin - Medizinische Klinik III, Berlin, Germany
- Zeisigwaldkliniken Bethanien Chemnitz GmbH, Chemnitz, Germany
- Universitätsklinikum Essen, Essen, Germany
- Klinik der Johann-Wolfgang-Goethe-Universität, Frankfurt am Main, Germany
- Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum (Onkologie / Hämatologie), Hamburg, Germany
- Universitätsklinikum Heidelberg - Klinik für Urologie, Heidelberg, Germany
- Universitätsklinikum Schleswig Holstein - Campus Lübeck, Lübeck, Germany
- Universitätsklinikum Mainz - 3. Medizinische Klinik, Mainz, Germany
- Klinikum der Universität - München Großhadern, Munich, Germany
- Urologische Klinik Dr. Castringius - München-Planegg, Planegg, Germany
- Universitätsklinikum Tübingen - Klinik für Urologie, Tübingen, Germany
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00523159 on ClinicalTrials.govOther trials for Clear cell renal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07128680Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell CancerCity of Hope Medical Center
- RECRUITINGPHASE2NCT06863311Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCCKarie Runcie
- RECRUITINGPHASE2NCT07397611Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCCDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT07188896A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)Brian Rini
- RECRUITINGPHASE2NCT07469683An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell CarcinomaYonsei University
- RECRUITINGPHASE1, PHASE2NCT07227415A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerPfizer
- RECRUITINGPHASE1, PHASE2NCT07551349Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell CarcinomaBeijing Biotech
- RECRUITINGPHASE2NCT07223541Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell CarcinomaUniversity of Oklahoma